Novartis Eye Drug Doesn't Infringe Rival's IP, UK Court Says

Law360, New York (October 11, 2012, 5:59 PM EDT) -- An appeals court in the U.K. said Wednesday that Novartis Pharmaceuticals U.K. Ltd.'s vision-loss drug Lucentis did not infringe technology patented by AstraZeneca PLC's MedImmune Ltd. unit, upholding a lower court ruling that found the patents invalid.

The U.K. Court of Appeal determined that Novartis's sale of Lucentis — a treatment for an eye condition known as wet age-related macular degeneration, or AMD, that can lead to loss or a limitation of a person's ability to see straight ahead — did not infringe one of MedImmune's...
To view the full article, register now.